IL235459A0 - Ways to treat non-small cell lung cancer - Google Patents

Ways to treat non-small cell lung cancer

Info

Publication number
IL235459A0
IL235459A0 IL235459A IL23545914A IL235459A0 IL 235459 A0 IL235459 A0 IL 235459A0 IL 235459 A IL235459 A IL 235459A IL 23545914 A IL23545914 A IL 23545914A IL 235459 A0 IL235459 A0 IL 235459A0
Authority
IL
Israel
Prior art keywords
lung cancer
small cell
cell lung
treating non
treating
Prior art date
Application number
IL235459A
Other languages
English (en)
Hebrew (he)
Inventor
Chen Duksin
Shoshi Tessler
Original Assignee
Teva Pharma
Chen Duksin
Shoshi Tessler
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teva Pharma, Chen Duksin, Shoshi Tessler filed Critical Teva Pharma
Publication of IL235459A0 publication Critical patent/IL235459A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5752—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the lungs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL235459A 2012-05-18 2014-11-02 Ways to treat non-small cell lung cancer IL235459A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261649092P 2012-05-18 2012-05-18
PCT/US2013/041652 WO2013173757A1 (en) 2012-05-18 2013-05-17 Method for treating non-small cell lung cancer

Publications (1)

Publication Number Publication Date
IL235459A0 true IL235459A0 (en) 2014-12-31

Family

ID=49581824

Family Applications (1)

Application Number Title Priority Date Filing Date
IL235459A IL235459A0 (en) 2012-05-18 2014-11-02 Ways to treat non-small cell lung cancer

Country Status (17)

Country Link
US (1) US20130310440A1 (enExample)
EP (1) EP2849761A1 (enExample)
JP (1) JP2015522542A (enExample)
KR (1) KR20150024843A (enExample)
CN (1) CN104684564A (enExample)
AR (1) AR091090A1 (enExample)
AU (1) AU2013262589A1 (enExample)
BR (1) BR112014028787A2 (enExample)
CA (1) CA2874092A1 (enExample)
EA (1) EA201492148A1 (enExample)
IL (1) IL235459A0 (enExample)
IN (1) IN2014DN10390A (enExample)
PH (1) PH12014502569A1 (enExample)
SG (1) SG11201407649RA (enExample)
TW (1) TW201402132A (enExample)
UY (1) UY34812A (enExample)
WO (1) WO2013173757A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ513757A (en) 1999-02-26 2004-12-24 Univ British Columbia Antisense oligonucleotides to inhibit TRPM-2 expression and delay androgen independance in prostatic tumour cells
US7569551B2 (en) 2000-02-25 2009-08-04 The University Of British Columbia Chemo- and radiation-sensitization of cancer by antisense TRPM-2 oligodeoxynucleotides
EP4122383B1 (en) 2010-05-08 2025-02-12 The Regents Of The University Of California Sem scanner sensing apparatus for early detection of ulcers
RU2013145869A (ru) 2011-03-15 2015-04-20 Дзе Юниверсити Оф Бритиш Коламбиа КОМБИНАЦИЯ ОЛИГОНУКЛЕОТИДА АНТИ-КЛАСТЕРИНА С ИНГИБИТОРОМ Hsp90 ДЛЯ ЛЕЧЕНИЯ РАКА ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫ
CN104473973B (zh) * 2014-12-19 2015-08-05 山东创新药物研发有限公司 一株戈氏梭菌驯化株的应用
US10182740B2 (en) 2015-04-24 2019-01-22 Bruin Biometrics, Llc Apparatus and methods for determining damaged tissue using sub-epidermal moisture measurements
EP3454866A4 (en) * 2016-05-13 2020-01-08 Golden Biotechnology Corporation METHOD AND COMPOSITIONS FOR TREATING ADVANCED NON-SMALL CELL LUNG CANCER
CA3042103A1 (en) 2017-02-03 2018-08-09 Bruin Biometrics, Llc Measurement of susceptibility to diabetic foot ulcers
KR102492905B1 (ko) 2017-02-03 2023-01-31 브루인 바이오메트릭스, 엘엘씨 조직 생존률의 측정
GB2569922B (en) 2017-02-03 2022-02-02 Bruin Biometrics Llc Measurement of edema
GB2574945A (en) 2017-11-16 2019-12-25 Bruin Biometrics Llc Providing a continuity of care across multiple care settings
AU2018380431B2 (en) 2017-12-07 2024-10-24 Bruin Biometrics, Llc SEM trend analysis
WO2019136287A1 (en) * 2018-01-05 2019-07-11 LifeUnit Inc. Adjuvant chemicals that prevent drug tolerance and persister formation by bacteria
PT3749181T (pt) 2018-02-09 2024-05-15 Bruin Biometrics Llc Deteção de lesões nos tecidos
AU2019359378B2 (en) 2018-10-11 2025-01-09 Bruin Biometrics, Llc Device with disposable element
US11642075B2 (en) 2021-02-03 2023-05-09 Bruin Biometrics, Llc Methods of treating deep and early-stage pressure induced tissue damage

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6900187B2 (en) * 1999-02-26 2005-05-31 The University Of British Columbia TRPM-2 antisense therapy using an oligonucleotide having 2′-O-(2-methoxy)ethyl modifications
US20060024692A1 (en) * 2002-09-30 2006-02-02 Oncotherapy Science, Inc. Method for diagnosing non-small cell lung cancers
US8710020B2 (en) * 2004-04-02 2014-04-29 The University Of British Columbia Clusterin antisense therapy for treatment of cancer
CA2728449A1 (en) * 2008-06-18 2009-12-23 Abbott Laboratories P/gf-1 companion diagnostic methods and products
CA2836676A1 (en) * 2011-05-19 2012-11-22 Teva Pharmaceutical Industries Ltd. Method for treating non-small cell lung cancer

Also Published As

Publication number Publication date
US20130310440A1 (en) 2013-11-21
WO2013173757A1 (en) 2013-11-21
UY34812A (es) 2013-12-31
AR091090A1 (es) 2014-12-30
BR112014028787A2 (pt) 2017-06-27
KR20150024843A (ko) 2015-03-09
CA2874092A1 (en) 2013-11-21
EA201492148A1 (ru) 2015-04-30
SG11201407649RA (en) 2014-12-30
EP2849761A1 (en) 2015-03-25
TW201402132A (zh) 2014-01-16
AU2013262589A1 (en) 2015-01-22
JP2015522542A (ja) 2015-08-06
PH12014502569A1 (en) 2015-01-21
IN2014DN10390A (enExample) 2015-08-14
WO2013173757A8 (en) 2015-04-30
CN104684564A (zh) 2015-06-03

Similar Documents

Publication Publication Date Title
IL288181A (en) Cancer treatment methods
IL274647A (en) Methods for treating non- small cell lung cancer using tor kinase inhibitor combination therapy
IL237791B (en) A method for treating cancer
PL3967315T3 (pl) Akkermansia muciniphila do leczenia nowotworu złośliwego
SG11201503893RA (en) Method of treating cancer
ZA201501914B (en) Method for enhancing specific immunotherapies in cancer treatment
IL235696A0 (en) A method for treating gd2 positive cancer
PL2542585T3 (pl) Sposoby leczenia nowotworu jelita grubego
IL228644A0 (en) Cancer treatment methods
ZA201906339B (en) Methods for treating pruritus
EP2895206A4 (en) METHOD FOR TREATING CARCINOMA
ZA201309254B (en) Method for treating non-small cell lung cancer
PL2876447T3 (pl) Sposób wykrywania nowotworu
GB201200279D0 (en) Vehicle rollback control apparatus and method
IL254964A0 (en) A method for treating breast cancer
GB2503068B (en) Ion guide construction method
PL2754441T3 (pl) Kompozycja do profilaktyki i leczenia niedrobnokomórkowego raka płuc, zawierająca pochodne pirazyno-triazynowe
GB2523708B (en) Method for ion production
EP2882420A4 (en) IMPROVED METHODS OF TREATING CANCER WITH REDUCED RENALER TOXICITY
HK1195735A (en) Method for treating non-small cell lung cancer
AU2012901918A0 (en) Methods for treating cancer
EP2707011A4 (en) METHOD FOR THE TREATMENT OF PROSTATE CANCER
GB201205136D0 (en) Ion guide construction method
IL232266A0 (en) Cancer treatment methods